Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

Amakem Raises €18M to Take Glaucoma Candidate Through Phase II Trials

Firm claims ROCK inhibitor AMA0076 reduces IOP but is enzyme-inactivated at nontarget sites to reduce side effects such as hyperemia.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

The Price of BRCA Testing

Is getting a genetic test worth the multi-thousand dollar price?

Suggest a Poll